3
Announcements
Trials
Browse
Landscape
Phase
Phase NA
1
Status
Completed
3
Withdrawn
1
Unknown
1
Active not recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gynecologic
1
Genitourinary
1
Gastrointestinal
1
CNS
1
Conditions
Prostatic Neoplasms
1
Metabolic Syndrome
1
Interventions
pembrolizumab
19
Docetaxel
16
Magnetic Resonance Spectroscopy
14
Prednisone
13
Radiotherapy
11
bicalutamide
10
Leuprolide
10
Abiraterone Acetate
9
Radiosurgery
8
Cyclophosphamide
8
Biopsy
8
avelumab
7
atezolizumab
6
Specimen Handling
6
Interleukin-2
6
Gemcitabine
6
Bevacizumab
6
Androgen Antagonists
6
tremelimumab
5
gallium 68 PSMA-11
5
apalutamide
5
acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide
5
Surveys and Questionnaires
5
Sunitinib
5
Paclitaxel
5
Metformin
5
Injections
5
Goserelin
5
Cisplatin
5
ALT-803
5
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Withdrawn
×
Diet
×
Genitourinary
×
Clear all
NCT03173807
2017-10-06
ProNEST
University of Pittsburgh
Phase NA
Withdrawn